Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei 317 is a specific strain of probiotic bacteria that has been investigated for its potential role in biodefense. Developed through research supported by the Estonian Science Foundation and conducted at the University of Tartu, this strain was evaluated in human volunteer studies to determine its safety, persistence in the gastrointestinal tract, and ability to modulate the host's immune response. The mechanism of action relies on the competitive exclusion of pathogens, production of antimicrobial metabolites (such as lactic acid), and stimulation of non-specific mucosal immunity. The primary goal of its development is to provide a biological shield or passive immunity to individuals who may be exposed to bioterrorism agents, enhancing their natural resistance to infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus paracasei 317.